Truvada Approved for HIV Prevention — Physician’s First Watch
Truvada Approved for HIV Prevention
The FDA has approved the first drug to reduce the risk for acquiring HIV — so-called preexposure prophylaxis.
Truvada, a combination of the antiretrovirals emtricitabine and tenofovir, is indicated for people at high risk for HIV and is to be used in conjunction with safer sex practices. Before taking Truvada, patients should be tested for HIV to confirm seronegativity.
Clinical trials found that daily Truvada reduced the risk for HIV by 42% in HIV-negative men and transgender women who have sex with men, and by 75% in heterosexual couples in which one partner was HIV positive.
Writing in HIV and ID Observations, Dr. Paul Sax observes: "The challenging issues of defining the best candidates for this strategy — and finding the providers to prescribe it — still remain, but FDA approval should at least help justify insurance coverage if clinicians choose to offer it to their patients."